Aligos Therapeutics (ALGS) Enterprise Value (2021 - 2025)
Aligos Therapeutics (ALGS) has disclosed Enterprise Value for 5 consecutive years, with -$77.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 109.84% year-over-year to -$77.8 million, compared with a TTM value of -$77.8 million through Dec 2025, down 109.84%, and an annual FY2025 reading of -$77.8 million, down 109.84% over the prior year.
- Enterprise Value was -$77.8 million for Q4 2025 at Aligos Therapeutics, up from -$156.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$35.4 million in Q3 2024 and bottomed at -$240.4 million in Q3 2021.
- Average Enterprise Value over 5 years is -$124.1 million, with a median of -$109.5 million recorded in 2022.
- The sharpest move saw Enterprise Value skyrocketed 72.68% in 2024, then crashed 340.87% in 2025.
- Year by year, Enterprise Value stood at -$187.0 million in 2021, then skyrocketed by 56.43% to -$81.5 million in 2022, then plummeted by 66.71% to -$135.8 million in 2023, then surged by 72.68% to -$37.1 million in 2024, then tumbled by 109.84% to -$77.8 million in 2025.
- Business Quant data shows Enterprise Value for ALGS at -$77.8 million in Q4 2025, -$156.2 million in Q3 2025, and -$227.2 million in Q2 2025.